A review of rituximab, the first anti-CD20 monoclonal antibody used in the treatment of B non-Hodgkin's lymphomas

被引：46

作者：

Feugier, Pierre ^{[1
,2
]}

机构：

[1] Ctr Hosp Univ Nancy, Serv Hematol, F-54511 Vandoeuvre Les Nancy, France

[2] Univ Lorraine, INSERM 954, Unite NGERE, F-54000 Nancy, France

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 09期

关键词：

CD20; monoclonal antibody; non-Hodgkin's lymphoma; STEM-CELL TRANSPLANTATION; DETUDE-DES-LYMPHOMES; HIGH-DOSE CHEMOTHERAPY; PROSPECTIVE RANDOMIZED-TRIAL; PROGRESSION-FREE SURVIVAL; RELAPSED FOLLICULAR LYMPHOMA; BENDAMUSTINE PLUS RITUXIMAB; 3-WEEKLY CHOP CHEMOTHERAPY; EVENT-FREE SURVIVAL; HIGH TUMOR BURDEN;

D O I：

10.2217/fon.15.57

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rituximab is a type I anti-CD20 monoclonal antibody, which stabilizes CD20 on lipid rafts, promoting antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. It is the first targeted therapy used in B-cell malignancies and has revolutionized their treatment, without excess of toxicity. In combination with chemotherapy, it has significantly improved response rates and progression-free survival and, for some of them, overall survival of patients with diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, mantle cell lymphoma. Moreover, it has been shown to improve progression-free survival in maintenance in follicular lymphoma as well as mantle cell lymphoma. Improvement of its efficacy includes exploration of resistance mechanisms, pharmacokinetics parameters, role of vitamin D and evaluation of subcutaneous route, among others.

引用

页码：1327 / 1342

页数：16

共 104 条

[81] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J].

Rummel, Mathias J. ;

Niederle, Norbert ;

Maschmeyer, Georg ;

Banat, G. Andre ;

von Gruenhagen, Ulrich ;

Losem, Christoph ;

Kofahl-Krause, Dorothea ;

Heil, Gerhard ;

Welslau, Manfred ;

Balser, Christina ;

Kaiser, Ulrich ;

Weidmann, Eckhart ;

Duerk, Heinz ;

Ballo, Harald ;

Stauch, Martina ;

Roller, Fritz ;

Barth, Juergen ;

Hoelzer, Dieter ;

Hinke, Axel ;

Brugger, Wolfram .

LANCET, 2013, 381 (9873) :1203-1210

[82] Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma [J].

Rummel, MJ ;

Al-Batran, SE ;

Kim, SZ ;

Welslau, M ;

Hecker, R ;

Kofahl-Krause, D ;

Josten, KM ;

Dürk, H ;

Rost, A ;

Neise, M ;

von Grünhagen, U ;

Chow, KU ;

Hansmann, ML ;

Hoelzer, D ;

Mitrou, PS .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3383-3389

[83] Comparison of Subcutaneous Versus Intravenous Administration of Rituximab As Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study [J].

Salar, Antonio ;

Avivi, Irit ;

Bittner, Beate ;

Bouabdallah, Reda ;

Brewster, Mike ;

Catalani, Olivier ;

Follows, George ;

Haynes, Andrew ;

Hourcade-Potelleret, Florence ;

Janikova, Andrea ;

Larouche, Jean-Francois ;

McIntyre, Christine ;

Pedersen, Michael ;

Pereira, Juliana ;

Sayyed, Pakeeza ;

Shpilberg, Ofer ;

Tumyan, Gayane .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (17) :1782-U62

[84] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [J].

Salles, Gilles ;

Seymour, John Francis ;

Offner, Fritz ;

Lopez-Guillermo, Armando ;

Belada, David ;

Xerri, Luc ;

Feugier, Pierre ;

Bouabdallah, Reda ;

Catalano, John Vincent ;

Brice, Pauline ;

Caballero, Dolores ;

Haioun, Corinne ;

Pedersen, Lars Moller ;

Delmer, Alain ;

Simpson, David ;

Leppa, Sirpa ;

Soubeyran, Pierre ;

Hagenbeek, Anton ;

Casasnovas, Olivier ;

Intragumtornchai, Tanin ;

Ferme, Christophe ;

da Silva, Maria Gomes ;

Sebban, Catherine ;

Lister, Andrew ;

Estell, Jane A. ;

Milone, Gustavo ;

Sonet, Anne ;

Mendila, Myriam ;

Coiffier, Bertrand ;

Tilly, Herve .

LANCET, 2011, 377 (9759) :42-51

[85] Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study [J].

Salles, Gilles ;

Mounier, Nicolas ;

de Guibert, Sophie ;

Morschhauser, Franck ;

Doyen, Chantal ;

Rossi, Jean-Francois ;

Haioun, Corinne ;

Brice, Pauline ;

Mahe, Beatrice ;

Bouabdallah, Reda ;

Audhuy, Bruno ;

Ferme, Christophe ;

Dartigeas, Caroline ;

Feugier, Pierre ;

Sebban, Catherine ;

Xerri, Luc ;

Foussard, Charles .

BLOOD, 2008, 112 (13) :4824-4831

[86] Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study [J].

Salles, Gilles A. ;

Morschhauser, Franck ;

Solal-Celigny, Philippe ;

Thieblemont, Catherine ;

Lamy, Thierry ;

Tilly, Herve ;

Gyan, Emmanuel ;

Lei, Guiyuan ;

Wenger, Michael ;

Wassner-Fritsch, Elisabeth ;

Cartron, Guillaume .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2920-+

[87] Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1) [J].

Schmitz, Norbert ;

Nickelsen, Maike ;

Ziepert, Marita ;

Haenel, Mathias ;

Borchmann, Peter ;

Schmidt, Christian ;

Viardot, Andreas ;

Bentz, Martin ;

Peter, Norma ;

Ehninger, Gerhard ;

Doelken, Gottfried ;

Ruebe, Christian ;

Truemper, Lorenz ;

Rosenwald, Andreas ;

Pfreundschuh, Michael ;

Loeffler, Markus ;

Glass, Bertram .

LANCET ONCOLOGY, 2012, 13 (12) :1250-1259

[88] High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial [J].

Schouten, HC ;

Qian, W ;

Kvaloy, S ;

Porcellini, A ;

Hagberg, H ;

Johnsen, HE ;

Doorduijn, JK ;

Sydes, MR ;

Kvalheim, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3918-3927

[89] Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis [J].

Schulz, Holger ;

Bohlius, Julia F. ;

Trelle, Sven ;

Skoetz, Nicole ;

Reiser, Marcel ;

Kober, Thilo ;

Schwarzer, Guido ;

Herold, Michael ;

Dreyling, Martin ;

Hallek, Michael ;

Engert, Andreas .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09) :706-714

[90] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J].

Sehn, Laurie H. ;

Berry, Brian ;

Chhanabhai, Mukesh ;

Fitzgerald, Catherine ;

Gill, Karamjit ;

Hoskins, Paul ;

Klasa, Richard ;

Savage, Kerry J. ;

Shenkier, Tamara ;

Sutherland, Judy ;

Gascoyne, Randy D. ;

Connors, Joseph M. .

BLOOD, 2007, 109 (05) :1857-1861

← 2 3 4 5 6 7 8 9 10 11 →